Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myel...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Dispenzieri, Angela, Buadi, Francis, Laumann, Kristina, LaPlant, Betsy, Hayman, Suzanne R., Kumar, Shaji K., Dingli, David, Zeldenrust, Steven R., Mikhael, Joseph R., Hall, Robert, Rajkumar, S. Vincent, Reeder, Craig, Fonseca, Rafael, Bergsagel, P. Lief, Stewart, A. Keith, Roy, Vivek, Witzig, Thomas E., Lust, John A., Russell, Stephen J., Gertz, Morie A., Lacy, Martha Q.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2012
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3369677/
https://ncbi.nlm.nih.gov/pubmed/22493299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-413161
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller